Alogliptin Benzoate (SYR-322) is a potent, selective, and orally active inhibitor of DPP-4 with an IC50 of <10 nM, exhibiting over 10,000-fold selectivity over DPP-8 and DPP-9. It is suitable for research into type 2 diabetes.
- Potent, selective, and orally active inhibitor of DPP-4.
- Inhibits LPS-induced extracellular signal-regulated kinase (ERK) phosphorylation in U937 cells.
- Inhibits LPS-stimulated MMP-1 secretion and mRNA expression mediated by the ERK pathway in U937 cells.
- Improves glucose tolerance and increases plasma insulin levels in female Wistar fatty rats.
- Reduces infarction area and improves brain vascular integrity in middle cerebral artery occlusion (MCAO) mice.